Apostle awards image06/2020: Apostle Inc selected to present at the 5th Liquid Biopsy Summit

Apostle Inc is pleased to announce that the company is going to present at the 5th Liquid Biopsy Summit, to take place in Seattle, WA on June 15-17, 2020. David Ge, CEO of Apostle, will discuss Apostle MiniEnrich, a novel method for enrichment of short DNA fragments for NIPT and oncology applications.

The fragment sizes of circulating free DNA show subtle variability from different origins, for example, fetal vs. maternal, cancer vs. normal. The current liquid biopsy technologies offer little resolution in differentiating and enriching for this small but important difference, resulting in sample rejections, test inaccuracies, and limited clinical utility of liquid biopsies. In the Summit, Apostle will present a novel method, termed Apostle MiniEnrich, to address this challenge and efficiently capture this subtle variability, with data showing significant enrichment of target cfDNA fragments (Average Fetal Fraction/FF before enrichment = 12.96%; Average FF after enrichment = 19.92%; Average Delta FF = 6.97%, P = 0.001). This method may have the potential to rescue rejected or non-reportable clinical samples and improve test accuracy, and may enable a much broader utility of liquid biopsies.

“I’m thrilled to join the prestigious speakers and organizations in the Summit.”, said David. “I would like to thank the Liquid Biopsy Summit and its Scientific Review Committee for selecting Apostle’s work.”

For more details of the Summit, visit: https://www.liquidbiopsysummit.com/programs.

Apostle awards image01/2020: Apostle Inc selected to present at PMWC 2020

01/2020: Apostle Inc selected to present at PMWC 2020 Liquid Biopsy Showcase

Apostle Inc is selected to present at the Precision Medicine World Conference (PWMC) 2020, held in Santa Clara Convention Center, California on January 21-24, 2020.

David Ge, CEO of Apostle Inc, attended the conference and presented in the conference’s Liquid Biopsy Showcase track. The PMWC 2020 Liquid Biopsy Showcase provides a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. The track features companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).

“cfDNA isolation, purification, and selection is a critical yet unaddressed challenge in liquid biopsy.” David said, “The acclaimed Apostle MiniMax high efficiency cfDNA isolation technology, as well as the new incoming Apostle MiniEnrich short-fragment cfDNA selection technology, answers for this challenge and ensures a successful liquid biopsy test.”

For more information, visit: https://www.pmwcintl.com/session/liquid-biopsy-showcase_2020sv/

Apostle awards image 10/2019: Independent studies presented at ASHG 2019

Beckman Coulter Beckman Coulter

Two independent studies were presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting, comparing paired FFPE tumor tissue and cfDNA samples, and paried whole blood and cfDNA samples. Majority of variants that are found when sequencing FFPE DNA could be captured by sequencing cfDNA. Variants found only in cfDNA compared with whole blood could be used as an initial screen for ctDNA analysis. cfDNA samples were prepared using the Apostle MiniMaxTM technology.

Reference

Apostle awards image 05/2019: Apostle MiniMax featured in Science, New Products section

05/2019: Apostle MiniMax featured in <i>Science</i>, New Products section image

Apostle MiniMax is featured in Science, New Products section, 2019;364(6441):696.

Reference

awards image04/2019: ISO13485:2016 & ISO9001:2015 (Menlo Park, CA, USA site)

Apostle ISO13485 image Apostle ISO9001 image

Apostle Inc is pleased to receive the Certificates of Conformance to certify that Quality Management System of Apostle Inc. 1455 Adams Dr. Menlo Park, CA 94025, USA has been assessed by ABS Quality Evaluations, Inc. and found to be in conformance with the requirements set forth by: ISO13485:2016, and ISO9001:2015. The Quality Management System is applicable to DEVELOPMENT, MANUFACTURING, LICENSING AND SALES OF CONSUMABLES AND CHEMICALS FOR NUCLEIC ACID RESEARCH.

To download the certificates:
ISO13485:2016 Certificate of Conformance
ISO9001:2015 Certificate of Conformance

Apostle awards image 04/2019: Independent study presented at AACR 2019

Beckman Coulter

An independent study was presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, comparing paired FFPE tumor tissue and cfDNA samples. Both FFPE and cfDNA detect at least two thirds of the observed indels and at least 90% of the observed SNVs. cfDNA samples were prepared using the Apostle MiniMaxTM technology.

Reference

awards image03/2019: ISO13485:2016 (Shenzhen, China site)

Apostle ISO13485 image

Apostle Inc is pleased to have been awarded ISO 13485 certification for our Nucleic Acid Extraction or Purification Reagents of Research and Development, Production, and Sales in our manufacturing facility located in Shenzhen, China. This certificate demonstrates our commitment to providing a high-quality and consistent service to our clients and our ongoing investment in technology, development, processes and procedures.

ISO 13485, Medical devices – Quality management systems – Requirements for regulatory purposes, is an internationally agreed standard that sets out the requirements for a quality management system specific to the medical devices industry. It has recently been revised, with the new version published in March 2016.

Apostle awards image 02/2019: Beckman Coulter Life Sciences Enters Liquid Biopsy Partnership with Apostle

Beckman Coulter

Beckman Coulter Life Sciences announces an exclusive partnership with Apostle, a liquid biopsy company, on Feb 28, 2019.

For more information about this partnership:
https://www.beckman.com/news/liquid-biopsy-partnership-with-apostle

Apostle awards image 02/2019: Independent validation study presented at AGBT 2019

Beckman Coulter

Apostle MiniMaxTM technology is independently validated and the findings are presented at the Advances in Genome Biology and Technology (AGBT) 2019 meeting in Marco Island, FL. Apostle MiniMaxTM is efficient, clean, scalable, automatable, versatile, and novel.

Reference

Apostle awards image 11/2018: Apostle and Apostle MiniMax trademarks registration

TM TM

Apostle Inc is pleased to receive the trademark registration certificates for APOSTLE and APOSTLE MINIMAX from the United States Patent and Trademark Office on Nov 21, 2018. The registration dates for both trademarks are July 24, 2018.

awards image09/2018: ISO9001:2015 (Shenzhen, China site)

Apostle ISO9001 image

Apostle Inc is pleased to have been awarded ISO 9001 certification for our R&D, Manufacturing and Sales of Nucleic Acid Extraction and Purification Kits in our manufacturing facility located in Shenzhen, China. This certificate demonstrates our commitment to providing a high-quality and consistent service to our clients and our ongoing investment in technology, development, processes and procedures.

ISO 9001 is the international standard that specifies requirements for a quality management system (QMS). Organizations use the standard to demonstrate the ability to consistently provide products and services that meet customer and regulatory requirements. It is the most popular standard in the ISO 9000 series and the only standard in the series to which organizations can certify.

Apostle awards image04/2018: Stanford University StartX

Apostle StartX image

Apostle StartX image

StartX is a renowned educational non-profit that accelerates the development of Stanford's top entrepreneurs through experiential education and collective intelligence. The Stanford-StartX Fund (SSF), co-founded by StartX, Stanford University, and Stanford Health Care is available only to StartX companies with a Stanford-affiliated founder.

StartX alumni and trusted expert judges review and determine which teams are accepted. The acceptance rate has been between 8%-10%. Apostle is selected into the StartX Accelerator Program (Summer 2018 session), following one initial review, four interviews and due diligence.

Apostle awards image01/2018: BioSpace Top 20 Life Science Startups

Apostle Top 20 image

Apostle Top 20 image

Apostle Inc is selected into the Top 20 Life Science Startups to Watch in 2018 by BioSpace on January 2, 2018. The NextGen Bio Class of 2018 is "a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015, a stellar group of companies that are already making an enormous impact on the industry now and will into the future."

Companies in the field of genomic sciences selected in the past three years include:

  • Freenome (Class of 2018): raised $77 million;
  • Grail (Class of 2017): raised $1.3 billion;
  • CRISPR (2016): IPO
  • Editas (2015): IPO
  • NextCode (2015): Acquired
Apostle awards image 11/2017: PCT patent application submission

Apostle PT image

Apostle Inc is pleased to submit its PCT patent application to the U.S. patent and trademark office on Nov 3, 2017.

Apostle awards image 09/2017: Finalist of North America Region, CACSC

Apostle CACSC image

Apostle won the Second Place in the Final of North America Region, CACSC,(Create@AlibabaCloud Startup Contest). Over 300 startups from North America have competed in CACSC, and 13 entered the final.

Apostle awards image08/2017: Amazon Web Service Activate Gold Premium Support

Apostle CACSC image

Apostle Inc is selected into the Amazon Web Service (AWS) Activate Program.The AWS Activate Program is designed for startups in select accelerators, incubators, Seed/VC Funds, and other startup-enabling organizations. Some of the world’s hottest startups, including Airbnb, Slack, and Robinhood, have leveraged the power of AWS to quickly scale.

Apostle awards image 07/2017: Apostle's 1st PCT patent application submission

Apostle PT image

Apostle Inc is pleased to submit its first PCT patent application to the U.S. patent and trademark office on July 25, 2017.

Apostle awards image07/2017: Forbes China 30 Under 30

Apostle Forbes 30u30 image

Forbes China named Apostle Inc’s co-Founder and VP of Chemistry, Bo Zhang, PhD, as one of the most brilliant young entrepreneurs in its annual “30 Under 30 China” list in the category of healthcare and science.

Apostle awards image 2002- Certification and License: ABMGG, States of California & New York, ACMG, Harvard Medical School

Apostle Inc’s co-Founder and SVP of Medicine, Wenqi Zeng, MD PhD is a board-certified clinical molecular geneticist and lab director holding certificates and licenses from American Board of Medical Genetics and Genomics (ABMGG), State of California, State of New York, and diploma from American College of Medical Genetics (ACMG), and Harvard Medical School Genetics Training Program.